An Electrifying Biotechnology – A Shot at Shocking Profits

Fascination with the effects of electricity on the body goes back — way back.

In the 1770s Italian physician and physicist Luigi Galvani shocked the world with the discovery that a spark could cause a dead frog’s legs to twitch.

In 1802, German chemist Johann Wilhelm Ritter furthered Galvani’s research into electrophysiology. He observed how halting a strong current in muscle nerves could cause a muscle to contract.

[Read more...]

An Electrifying Biotechnology – A Shot at Shocking Profits

Fascination with the effects of electricity on the body goes back — way back.

In the 1770s Italian physician and physicist Luigi Galvani shocked the world with the discovery that a spark could cause a dead frog’s legs to twitch.

In 1802, German chemist Johann Wilhelm Ritter furthered Galvani’s research into electrophysiology. He observed how halting a strong current in muscle nerves could cause a muscle to contract.

[Read more...]

Catastrophically Successful Life Extension

Truly historic discoveries and therapies are coming online right now that will radically decrease the threat and cost of autoimmune disorders, cancers, cardiovascular disease, Alzheimer’s, arthritis, obesity and diabetes, as well as dangerous influenzas, HIV and other virus-borne diseases. Regular readers know that I’m referring to companies in our portfolio.

[Read more...]

The Generic Drug Boom

[What counts is] competition from the new commodity, the new technology, the new source of supply, the new type of organization… competition which… strikes not at the margins of the profits and the outputs of the existing firms, but at their foundations and their very lives.

[Read more...]

The “Shadow Pharmaceutical” Sector

The business of medical biotechnologies operates within an extraordinarily complex regulatory system.

The SEC and the IRS are only the beginning of the story…

In the United States, the Food and Drug Administration determines what can legally be sold. It even exercises control over what can be said by companies about medical therapies. Elsewhere, other regulatory authorities play similar roles.

[Read more...]

Solving the Sickle Cell Crisis

The sickle cell trait has its origins in a genetic adaptation common in individuals in which the mosquito-borne disease, malaria, has impacted human life for thousands of years. In sub-Saharan Africa, for example, as many as one-third of people carry the gene. It is also found, although less commonly, in populations ringing the Mediterranean, such as North Africa, Spain, Greece and Italy.

[Read more...]

Antibiotics, the Next Generation!

Scientists are very interested in bacteria for a number of reasons. Among the most recent is that they can be used to manufacture various important chemicals, including fuels.

We tend not to think about it, but the single-cell microorganisms categorized as bacteria are the dominant life form on Earth. In some mathematical sense, this is their planet and we just use it.

[Read more...]

Outwitting Cancer’s “Deadly Fog”

The world-famous Ludwig Institute for Cancer Research in Belgium is funding a Phase 1/2 clinical test of a cancer vaccine. This complex carbohydrate blocks galectin-3s.

Briefly, galectins-3s are proteins that have the ability to recognize and attach themselves to specific sugar molecules. This sugar-binding characteristic is typical of all lectins and is essential to our bodies’ functioning, but galectin-3s, for some reason, are also involved in all manner of disorders. Galectin-3s are integrally involved in strokes, heart disease, cancers, inflammation and fibrosis in its many health-destroying forms.

[Read more...]

The Folly of Intellectuals

I have referred often to a theory of business cycles that was first described by the Austrian Joseph Schumpeter, but amplified by contemporary American Thomas Sowell. Both are brilliant economists who have described in mathematical detail how free markets produce the most wealth and well-being for society, including for those at the lower end of the financial spectrum.

[Read more...]